Clinical applications - Clinical development - Clinical trial PERFECT

Clinical trial: PERFECT

Intramyocardial injection of CD133+ stem cells in addition to bypass surgery in chronic ischemia.

The PERFECT trial is a randomized, placebo-controlled, double-blind study that will enroll 144 patients in Germany who are indicated for bypass surgery. The primary endpoint of the trial is to determine whether autologous bone marrow CD133+ stem cells yield a functional benefit in addition to the coronary artery bypass graft (CABG) operation as determined by left ventricular heart function (LVEF) by cardiac magnetic resonance imaging (MRI).

Status: ongoing Identifier: NCT00950274

Customer login


Forgot password?
Register for account

0 Shopping cart


Miltenyi Biotec Inc.
Phone: +1 800 FOR MACS
Fax:+1 877 591 1060
Contact overview

Product finder

Antibody panel builder



Change country

Please select your country to continue